<?xml version="1.0" encoding="UTF-8"?>
<p>CMV infection induces sustained functional T cell responses that are stronger in the long-term than the immune response to any other infectious pathogen [
 <xref rid="ppat.1008036.ref009" ref-type="bibr">9</xref>]. Experiments in the mouse model have shown that defined CMV epitope-specific CD8
 <sup>+</sup> T cells accumulate in tissues and blood and are maintained at stable high levels during mouse CMV (MCMV) latency [
 <xref rid="ppat.1008036.ref010" ref-type="bibr">10</xref>]. This phenomenon was termed ‘‘Memory Inflation” [
 <xref rid="ppat.1008036.ref011" ref-type="bibr">11</xref>]. While some MCMV derived peptides, as the ones derived from the IE3 (
 <sub>
  <bold>416</bold>
 </sub>
 <bold>RALEYKNL</bold>
 <sub>
  <bold>423</bold>
 </sub>) and M139 proteins (
 <sub>
  <bold>419</bold>
 </sub>
 <bold>TVYGFCLL</bold>
 <sub>
  <bold>426</bold>
 </sub>) induce inflationary responses, other peptides, such as the M45-derived (
 <sub>
  <bold>985</bold>
 </sub>
 <bold>HGIRNASFI</bold>
 <sub>
  <bold>993</bold>
 </sub>), induce conventional CD8
 <sup>+</sup> T cell response [
 <xref rid="ppat.1008036.ref012" ref-type="bibr">12</xref>]. Antigen-experienced CD8
 <sup>+</sup> T cells are subdivided into CD62L
 <sup>-</sup> effector memory (CD8T
 <sub>EM</sub>) and CD62L
 <sup>+</sup> central memory CD8
 <sup>+</sup> T cells (CD8T
 <sub>CM</sub>). The antigen-specific CD8
 <sup>+</sup> T cells during latent infection bear predominantly a CD8T
 <sub>EM</sub> phenotype and localize in secondary lymphoid or non-lymphoid organs [
 <xref rid="ppat.1008036.ref013" ref-type="bibr">13</xref>]. They may provide immune protection against diverse viral targets [
 <xref rid="ppat.1008036.ref014" ref-type="bibr">14</xref>–
 <xref rid="ppat.1008036.ref018" ref-type="bibr">18</xref>], but also against bacterial [
 <xref rid="ppat.1008036.ref019" ref-type="bibr">19</xref>] or tumor antigens [
 <xref rid="ppat.1008036.ref020" ref-type="bibr">20</xref>, 
 <xref rid="ppat.1008036.ref021" ref-type="bibr">21</xref>]. The exceptionally long-lasting cellular immunity to CMV antigens has raised the interest in CMV as a potential new vaccine vector [
 <xref rid="ppat.1008036.ref014" ref-type="bibr">14</xref>]. Many studies have demonstrated of optimal design of such CMV-based vaccines display efficient protection against virus infection such as rhesus macaque CMV (RhCMV) based Ebola [
 <xref rid="ppat.1008036.ref022" ref-type="bibr">22</xref>] and SIV [
 <xref rid="ppat.1008036.ref023" ref-type="bibr">23</xref>] vaccines and MCMV based Ebola virus vaccines [
 <xref rid="ppat.1008036.ref015" ref-type="bibr">15</xref>]. 
 <italic>Erkes</italic>, 
 <italic>D</italic>.
 <italic>A</italic>. 
 <italic>and Qiu</italic>, 
 <italic>Z</italic>. et al. demonstrated that CMV based vaccine vectors provide protection in suppressing tumors [
 <xref rid="ppat.1008036.ref024" ref-type="bibr">24</xref>, 
 <xref rid="ppat.1008036.ref025" ref-type="bibr">25</xref>].
</p>
